Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Diabetic Medicine : a Journal of the British Diabetic Association|August 14, 1998
Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitusA Mitrakou, N Tountas, A E Raptis, et al.
Bioconjugate Chemistry|May 1, 1994
Enhanced stability in vitro and in vivo of immunoconjugates prepared with 5-methyl-2-iminothiolaneS F Carroll, S L Bernhard, D A Goff, et al.
The Journal of Biological Chemistry|April 1, 1994
Gelonin analogs with engineered cysteine residues form antibody immunoconjugates with unique propertiesM Better, S L Bernhard, D M Fishwild, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1973
Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agentD G Streeter, J T Witkowski, G P Khare, et al.
Shock (Augusta, Ga.)|February 1, 1996
A phase I safety and pharmacokinetic study of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in healthy male volunteersR J Bauer, M L White, N Wedel, et al.
Infection and Immunity|July 19, 2000
Induction of proinflammatory cytokines from human respiratory epithelial cells after stimulation by nontypeable Haemophilus influenzaeD L Clemans, R J Bauer, J A Hanson, et al.
Cancer Research|July 15, 1989
Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugateL M Weiner, J O'Dwyer, J Kitson, et al.
The Journal of Biological Chemistry|June 23, 1995
T cell-targeted immunofusion proteins from Escherichia coliM Better, S L Bernhard, R E Williams, et al.
Carcinogenesis|October 23, 2019
Differential localization of PD-L1 and Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck squamous cell carcinomaD Schulz, M Streller, G Piendl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effectsR M Bukowski, G T Budd, J A Gibbons, et al.
Pageof 3